{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:35:02Z","timestamp":1788222902756,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-18-IBHU-0002"],"award-info":[{"award-number":["ANR-18-IBHU-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105899","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:10:32Z","timestamp":1763658632000},"page":"105899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Precision medicine strategy in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"10","author":[{"given":"A.","family":"Tarabay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Swales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Akoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Val\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fuerea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Bani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Barbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105899_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105899_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105899_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105899_bib5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105899_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105899_bib7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105899_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular pathogenesis of pancreatic cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105899_bib9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105899_bib10","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2025.105899_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113497","article-title":"Precision medicine for KRAS wild-type pancreatic adenocarcinomas","volume":"197","author":"Ben-Ammar","year":"2024","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105899_bib12","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105899_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105899_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105899_bib15","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105899_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00535-025-02253-9","article-title":"Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database","volume":"60","author":"Endo","year":"2025","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.esmoop.2025.105899_bib17","article-title":"A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer","volume":"7","author":"Hussung","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105899_bib18","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4251\/wjgo.v16.i7.2902","article-title":"Role of molecular biology in the management of pancreatic cancer","volume":"16","author":"Boileve","year":"2024","journal-title":"World J Gastrointest Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105899_bib19","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105899_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","article-title":"KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities","volume":"39","author":"Luchini","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105899_bib21","article-title":"514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"211","author":"Wolpin","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105899_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105899_bib23","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105899_bib24","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"7592","key":"10.1016\/j.esmoop.2025.105899_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2025.105899_bib26","article-title":"Codon-specific KRAS mutations predict survival in advanced pancreatic cancer","volume":"3","author":"Boil\u00e8ve","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2025.105899_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102973","article-title":"Medical management of pancreatic cancer: from personalization to broadening treatment strategies","volume":"138","author":"Dusetti","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105899_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3390\/jpm12111870","article-title":"Targeting KRAS in pancreatic cancer","volume":"12","author":"Cowzer","year":"2022","journal-title":"J Pers Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105899_bib29","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.annonc.2022.08.089","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"33","author":"Bayle","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105899_bib30","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-17-0899","article-title":"Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105899_bib31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.pan.2025.06.013","article-title":"Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma","volume":"25","author":"Furukawa","year":"2025","journal-title":"Pancreatology"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T03:53:22Z","timestamp":1773633202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017685"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105899","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine strategy in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105899"}}